IL-17A, the best known of these cytokines, has been linked to the pathogenesis of autoimmune and chronic inflammatory diseases, and its blockade with monoclonal antibodies has proved efficacious in psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Here, IL17A is linked to psoriasis.